Improved molecular imaging contrast agent for detection of human thrombus

Molecular imaging of microthrombus within fissures of unstable atherosclerotic plaques requires sensitive detection with a thrombus‐specific agent. Effective molecular imaging has been previously demonstrated with fibrin‐targeted Gd‐DTPA‐bis‐oleate (BOA) nanoparticles. In this study, the relaxivity of an improved fibrin‐targeted paramagnetic formulation, Gd‐DTPA‐phosphatidylethanolamine (PE), was compared with Gd‐DTPA‐BOA at 0.05‐4.7 T. Ion‐ and particle‐based r1 relaxivities (1.5 T) for Gd‐DTPA‐PE (33.7 (s*mM)‐1 and 2.48 × 106 (s*mM)‐1, respectively) were about twofold higher than for Gd‐DTPA‐BOA, perhaps due to faster water exchange with surface gadolinium. Gd‐DTPA‐PE nanoparticles bound to thrombus surfaces via anti‐fibrin antibodies (1H10) induced 72% ± 5% higher change in R1 values at 1.5 T (ΔR1 = 0.77 ± 0.02 1/s) relative to Gd‐DTPA‐BOA (ΔR1 = 0.45 ± 0.02 1/s). These studies demonstrate marked improvement in a fibrin‐specific molecular imaging agent that might allow sensitive, early detection of vascular microthrombi, the antecedent to stroke and heart attack. Magn Reson Med 50:411–416, 2003. © 2003 Wiley‐Liss, Inc.

[1]  R Weissleder,et al.  Targeted contrast agents in MR imaging. , 1996, Magnetic resonance imaging clinics of North America.

[2]  T Suzuki,et al.  Considerable Time From the Onset of Plaque Rupture and/or Thrombi Until the Onset of Acute Myocardial Infarction in Humans: Coronary Angiographic Findings Within 1 Week Before the Onset of Infarction , 2000, Circulation.

[3]  N Bom,et al.  Characterization of plaque components and vulnerability with intravascular ultrasound elastography. , 2000, Physics in medicine and biology.

[4]  S. Karlik,et al.  A liposomal MRI contrast agent: Phosphatid ylethanolamine‐DTPA , 1989, Magnetic resonance in medicine.

[5]  Stasia A. Anderson,et al.  Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .

[6]  P. Constantinides,et al.  Plaque fissures in human coronary thrombosis , 1966 .

[7]  M. Cerqueira Current status of radionuclide tracer imaging of thrombi and atheroma. , 1999, Seminars in nuclear medicine.

[8]  S A Wickline,et al.  Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. , 2000, Magnetic resonance in medicine.

[9]  G. Bearman,et al.  Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis , 1996, The Lancet.

[10]  M. L. Wood,et al.  Proton relaxation enhancement , 1993, Journal of magnetic resonance imaging : JMRI.

[11]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[12]  V. Fuster,et al.  Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.

[13]  J. Gladman,et al.  Direct magnetic resonance imaging of carotid artery thrombus in acute stroke , 1999, The Lancet.

[14]  B. de Kruijff,et al.  Effects of tumbling and lateral diffusion on phosphatidylcholine model membrane 31P-NMR lineshapes. , 1980, Biochimica et biophysica acta.

[15]  S. H. Koenig,et al.  The design of liposomal paramagnetic mr agents: effect of vesicle size upon the relaxivity of surface‐incorporated lipophilic chelates , 1992, Magnetic resonance in medicine.

[16]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[17]  J. G. Miller,et al.  In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. , 1998, The Journal of the Acoustical Society of America.

[18]  E. Purcell,et al.  Effects of Diffusion on Free Precession in Nuclear Magnetic Resonance Experiments , 1954 .